The Riskguard® test helps you help your patients


Gene panel
Specimen requirements
Turnaround time


Hereditary cancer is common
Hereditary cancers, which account for approximately 10-15% of cancer diagnoses, are caused by pathogenic germline variants and are often associated with early onset cancer, aggressive forms of cancer, and multiple cancer diagnoses in an individual and/or family.

Testing is under-utilized
It is estimated that only 7% of patients with cancer have received germline genetic testing,
Colorectal Breast Prostate Pancreatic Ovarian Endometrial Skin Gastric Kidney Endocrine Lung


Customize a risk-management path
- Lifestyle changes
- Screening programs
- Risk-reducing medication
- Risk-reducing surgeries

Inform optimal treatment
- Surgical options
- Increased surveillance
- Targeted therapies
More ways to personalize patient care
Pair the Riskguard test with our
Add the Riskguard test with our
We keep it simple and actionable
We want our results to be simple yet powerful. That's why we only report on variants in genes you can do something about based on guidelines and published literature. We provide easy-to-understand results that providers and patients can use for personalized care planning.
Negative sample report
Positive sample report
Uncertain sample report

Complete access to our premium customer support before, during, and after testing
On-demand customer care
Call our customer care team for general questions. You can request Riskguard test kits, and ask about billing, ordering, and how to access results.
Genetic support for your patients
Genetic support for you
Patient education on demand

Billing is easy when you have a support team like ours
- Coverage for eligible patients including Medicare and commercial insurance
* - Specialized support for billing insurance and prior authorization
- Flexible payment options for patients


Ordering a test for your patients is fast and easy
Ordering a test for your patients is fast and easy
We're here for you
Frequently asked questions
References
- Medicare and commercial insurance plans have specific inclusion criteria based on personal and family history of cancer.
- Estimated turnaround times based on data on file from previous testing, actual turnaround times may vary.
- There may be patient cost associated with independent genetic counseling services.
- LS-related cancers include colorectal, endometrial, gastric, ovarian, pancreatic, urothelial, brain(usually glioblastoma), biliary tract, and small intestine, as well as sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas as seen in Muir-Torre syndrome.
- DeBortoli E, McGahan E, Yanes T, et al., Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer, Cancer Med 2025;14(15):e71080.
- Kurian AW, Abrahamse P, Furgal A, et al. Germline Genetic Testing After Cancer Diagnosis. JAMA 2023;330(1):43-51.
- Idos GE, Kurian AW, Ricker C, et al. Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. JCO Precis Oncol 2019:3:PO.18.00217.
- Geyer CE Jr, Garber JE, Gelber RD, et al. OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250-1268.
- Hussain M, Mateo J, Fizazi K, et al. PROfound Trial Investigators. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345-2357.
- Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-327.
- Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852-861.
- Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
- Prospective Lynch Syndrome Database. Metachronous colorectal cancer risks after extended or segmental resection in MLH1, MSH2, and MSH6 Lynch syndrome: multicentre study from the Prospective Lynch Syndrome Database; Br J Surg 2025;1112(4):znaf061.
- Bedrosian I, Somerfield MR, Achatz MI, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol. 2024;42(5):584-604.
- Gressel GM, Frey MK, Norquist B, et al. Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement. Gynecol Oncol. 2024:181:170-178
- Stoffel EM, McKernin SE, Brand R, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2019;37(2):153-164
- Heald B, Hampel H, Church J, et al. Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Fam Cancer. 2020;19(3):223-239.
- Yu EY, Rumble RB, Agarwal N, et al. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J Clin Oncol. 2025;43(6):748-758.